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Microbial biocontainment is an essential goal for engineering safe, next-generation living
therapeutics. However, the genetic stability of biocontainment circuits, including kill switches,
is a challenge that must be addressed. Kill switches are among the most difﬁcult circuits to
maintain due to the strong selection pressure they impart, leading to high potential for
evolution of escape mutant populations. Here we engineer two CRISPR-based kill switches in
the probiotic Escherichia coli Nissle 1917, a single-input chemical-responsive switch and a
2-input chemical- and temperature-responsive switch. We employ parallel strategies to
address kill switch stability, including functional redundancy within the circuit, modulation of
the SOS response, antibiotic-independent plasmid maintenance, and provision of intra-niche
competition by a closely related strain. We demonstrate that strains harboring either kill
switch can be selectively and efﬁciently killed inside the murine gut, while strains harboring
the 2-input switch are additionally killed upon excretion. Leveraging redundant strategies, we
demonstrate robust biocontainment of our kill switch strains and provide a template for
future kill switch development.
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robiotic microbes have become effective chasses for engineering diagnostic and therapeutic technologies. One of the
most commonly engineered probiotic strains is Escherichia
coli Nissle 1917 (EcN). Engineered strains of EcN have been
successfully used to diagnose and treat bacterial infections1,2,
cancers3–5, gastrointestinal bleeding6, inﬂammatory disorders7–9,
and obesity10 in a variety of animal models. EcN strains engineered to treat metabolic disorders are being evaluated in human
clinical trials with promising early-phase results11,12. However,
there are important safety concerns associated with organisms
genetically engineered for medical applications. Probiotics are
living organisms that have the potential to mutate and evolve
undesirable traits over the course of diagnosis or treatment. Such
adaptations can include loss of beneﬁcial functions of the engineered system, gain of deleterious functions such as competitive
exclusion of native microbes, pathogenic potential against the
host, or environmental contamination if they spread outside the
host13–16. To mitigate these concerns, engineered probiotics
should possess biocontainment systems that enable both selective
removal from the host and prevent their environmental
dissemination17.
Biocontainment circuit designs are focused on preventing
proliferation in the wild, and typically involve an input that is
speciﬁc to the permissive environment and repressive to the
killing circuit, such that upon exit of the permissive environment,
the lethal components are expressed18. Several such biocontainment strategies have been developed with varying degrees of
efﬁcacy and stability, including use of auxotrophy11,19,20 and
synthetic amino acids21–23. While approaches like synthetic
auxotrophy are evolutionarily stable in that they do not readily
give rise to escape mutants21, a limitation of these methods is that
they may require the probiotic environment to be supplemented
with additional survival factors (‘permissive molecules’). Completely withholding these molecules in the gut, for example by
administering an auxotrophic strain without the essential compound, effectively limits probiotic lifespan in vivo11, but it may
also limit therapeutic potential depending on the rate of probiotic
cell death in the absence of the permissive molecules. Alternatively, the permissive molecules may theoretically be supplied
to patients in conjunction with the probiotic, but this design
complicates administration as well as the selective removal of
probiotics from the gut since the time to full clearance of the
permissive molecules may be difﬁcult to control. In addition, if
the permissive molecules are natively present in the gut, these
circuits can be compromised by cross-feeding20,21,24.
An inverse kill switch design would then be one in which the
baseline state in the gut is permissive without supplementation of
exogenous molecules; correspondingly, the lethal components of the
circuit are expressed in response to supplied inducers, or environmental signals external to the gut. Numerous genetic circuits have
been developed that initiate cell death in response to a chemical
inducer25–28. Similarly, biocontainment circuits have been developed
in E. coli using temperature sensors tuned to differentiate physiological and environmental temperatures18,29,30. These kill switches
control cell survival using a variety of mechanisms, including
expression of toxins and lysis proteins18,25–27, degradation of
essential proteins26, and cleavage and degradation of the genome by
Cas3 proteins28. Both temperature-sensitive circuits designed by
Piraner et al. and Stirling et al. used the E. coli CcdB-CcdA toxinantitoxin system to control cell survival. The kill switch engineered
by Piraner et al. used a modiﬁed version of the Salmonella typhimurium-native PtlpA-tlpA sensor and achieved a 4-log reduction in
fecal cell number30, while the kill switch engineered by Stirling et al.
used the E. coli-native PcspA promoter and achieved a 5-log reduction in fecal cell number29. Notably, functional redundancy offered
by the combination of the PcspA-controlled temperature-sensitive kill
2

switch with an orthogonal pH-sensitive kill switch mechanism
synergistically improved in vitro killing efﬁcacy such that surviving
colony counts were below the 11-log limit of detection18. However,
kill switches that induce cell death by expressing toxins, lysis proteins, and proteases are prone to mutational inactivation, often
leading to population dominance of non-functional variants, or have
not been characterized for genetic stability26. To overcome this
stringent evolutionary selection, such kill switch systems must be
designed to be highly stable. The temperature-inducible toxin-antitoxin kill switch engineered by Stirling et al. was shown to be stable
over 140 generations of growth in vitro and at least 10 days of
growth in the mouse gut29, while the combined temperature- and
pH-inducible kill switch was stable over at least 100 generations
in vitro18. In contrast, a CRISPR-Cas3-based system has been shown
to be stable for 1700 generations when applied to plasmid removal28.
However, it is unclear whether the same stability would persist if the
system was applied to cell death.
To engineer a genetically stable probiotic with viability that is
controllable both inside and outside the host, we used a step-wise
design approach to develop two CRISPR-Cas9-based kill switches
(CRISPRks) in EcN. First, we built a single-input kill switch that can
initiate probiotic death in response to the chemical inducer anhydrotetracycline (aTc). After iterative optimization for stability and
efﬁcacy, this circuit became the foundation for a 2-input kill switch
that can additionally initiate death in response to the temperature
decrease that occurs upon excretion from the host. Both designs
allow the engineered microbe to be selectively removed in situ from
the gut, while the ﬁnal 2-input CRISPRks additionally prevents the
microbe from surviving outside the body. To achieve genetic stability of the kill switches, we applied parallel approaches of genetic
engineering and environmental control, including functionally
redundant expression cassettes, antibiotic-free plasmid maintenance
systems, knockouts of key drivers of DNA-mutagenesis in the SOS
response, and provision of intra-niche microbial competition. Both
kill switches exhibited signiﬁcant long-term stability, with efﬁcient
killing maintained after 28 days (224 generations) of continuous
growth in vitro. In mice, we innovatively leveraged intra-niche
competitive inhibition to selectively disadvantage the target EcN
subpopulation31. The single-input CRISPRks allowed the engineered probiotic to be completely eliminated from the mouse gut in
response to aTc consumption. Similarly, the 2-input CRISPRks
achieved virtually complete eradication of the probiotic population
when both chemical- and temperature-induction were applied. The
principles and genetic parts used in the CRISPRks described here
(i.e., Cas9 and guide RNA) have been employed in various
microbial species32–34, in contrast to the limited use of Cas3 in
microbes, highlighting the potential for deploying this generalizable
biocontainment platform to other engineered probiotic and
microbial strains for diverse applications.
Results
Development of a chemical-inducible CRISPR-based kill
switch for EcN. We ﬁrst designed a kill switch that induces EcN
cell death in response to the chemical inducer aTc (Fig. 1a; Table 1).
To initiate cell death, we utilized a CRISPR/Cas9-based approach. E.
coli can repair double-stranded DNA breaks (DSBs), as caused by
Cas9, through RecA-dependent homologous recombination with
sister genomes generated by DNA replication35. However, the
damage caused by Cas9 is lethal if each copy of the replicating
genome is cut36. To make CRISPR-based cell death dependent on
the presence of aTc, we expressed Cas9 from a low-copy plasmid
and genome-targeting guide RNAs (gRNAs) from a medium-copy
plasmid using aTc-inducible Ptet promoters.
We next sought a gRNA that could target the genome and
initiate cell death with high efﬁciency. We hypothesized that
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Fig. 1 Development of a chemical-inducible CRISPR-based kill switch for EcN. a Schematic of the aTc-inducible CRISPR-based kill switch. Cas9 and
gRNAs are expressed on independent plasmids by aTc-inducible Ptet promoters. TetR, which regulates the expression of Ptet promoters in an aTcdependent manner, is constitutively expressed on the gRNA plasmid. In the presence of aTc, TetR is unable to bind to its target promoters, leading to
expression of Cas9 and the gRNAs. The Cas9/gRNA complex then binds to and cleaves its genomic targets, leading to cell death. b gRNA target locations
in the EcN genome: the single copy groL gene (gray), the three copy ileTUV genes (blue), and the seven copy rrsABCDEGH genes (green). c Log10 CFUs for
the no gRNA control and six gRNA expression plasmids in wild-type EcN with the Ptet-cas9 expression plasmid. d Sequencing results from 30 survivors
from c with non-functional ile-2 kill switches. e Genomic neutral integration sites used for Ptet-cas9 integrations: within the lacZ gene, between rhtB and
rhtC, between agaI and rsmI, and between exo and cea. f Log10 Fraction Viable for EcN strains with plasmid-based, one genome-integrated (Int X1), two
genome-integrated (Int X2), three genome-integrated (Int X3), and four genome-integrated (Int X4) Ptet-cas9 expression cassettes. All strains contain the
same ile-2 gRNA plasmid. g Sequencing results from 24 survivors from f with non-functional Int X4 kill switches. h Log10 CFUs for EcN with four genomic
Ptet-cas9 integrations and different combinations of the groL-2 and ile-2 gRNAs. ‘+opt’ represents the respective Ptet-gRNA cassette with an optimized Ptet
promoter. aTc concentration was increased to 500 ng/mL, from 100 ng/mL in c, based on the transfer curve characterized in Supplementary Fig. 1e. For all
sequencing, the fraction mutated is the fraction of total sequenced cassettes that contained a mutation. For all kill switch assays, exponential phase cells for
each strain were induced with 0 and 100 or 500 ng/mL aTc for 1.5 h. Values and error bars are the average and standard deviation of biological triplicate,
respectively. Statistical comparisons were performed using two-tailed unpaired t-tests (*P < 0.05; **P < 0.01; ***P < 0.001). See also Supplementary Fig. 1.
Source data with p-values are provided as a Source Data ﬁle.

gRNAs with multiple genomic binding sites would have higher
killing efﬁciencies as the gRNA-Cas9 complex would have a
higher probability of locating a target site. In addition, multilocus genome cleavage should decrease the probability of DSB
rescue through homologous recombination37, or genomic mutations in the target sites rendering the cell immune to the kill

switch. To explore the effect of target copy number, we tested the
aTc-response of six total gRNAs for three target genes present at
various copies throughout the genome: the single-copy groL gene,
the three-copy ileTUV genes, and the seven-copy rrsABCDEGH
genes (Fig. 1b, c). To quantify the efﬁciency for each gRNA, we
deﬁned the term ‘fraction viable’ as the ratio of colony forming
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Table 1 Names and descriptions of each no gRNA control and kill switch strain. Cas9-expressing plasmids include a low (~5)copy pSC101 origin of replication and gRNA-expressing plasmids include a medium (~20)-copy p15A origin of replication.
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units (CFUs) obtained in the non-permissive condition (+aTc) to
CFUs obtained in the permissive condition (−aTc). Interestingly,
the killing efﬁciencies for the multi-target gRNAs did not exceed
the efﬁciencies of the single-target gRNAs. At least one gRNA for
each target gene achieved a fraction viable of 10−4–10−5. The kill
switch rapidly triggered cell death, with maximum killing
efﬁciencies detected after just 1.5 h of aTc induction (Supplementary Fig. 1a). However, efﬁciencies were signiﬁcantly reduced by
2.5 h of induction, suggesting that a subpopulation of cells
harboring inactive kill switches were able to repopulate.

Improving kill switch stability through functional redundancy.
To determine the source of kill switch inactivation, we identiﬁed
isolates exhibiting loss-of-function from the aTc-induction assay,
and sequenced the cas9, gRNA, and tetR expression cassettes.
While a small number of isolates harbored mutated gRNA
(10 ± 14%) and tetR (3 ± 6%) cassettes, a large majority harbored
mutated cas9 expression cassettes (80 ± 19%), with mutations
predominantly in the Ptet promoters (Fig. 1d). To decrease the
probability of Cas9 expression inactivation, we integrated functionally redundant Ptet-cas9 expression cassettes into four genomic neutral integration sites11 (Fig. 1e). Each successive
integration improved the efﬁciency of the ile-2 gRNA kill switch,
with the four Ptet-cas9 integration strain (Int X4) achieving a
fraction viable 10 times lower than the plasmid-based Cas9
expression strain (Fig. 1f). Chromosomal expression of four
functionally redundant Cas9 cassettes did not alter the relative
efﬁciency of the six gRNAs (Supplementary Fig. 1b).
4

Figs. 4b, 4d, 4e, 5b,
5e, 5f

Diminishing returns were observed by the fourth Ptet-cas9
integration, suggesting a shift in inactivation method. We
sequenced non-functional Int X4 isolates and identiﬁed the
promoter of the Ptet-gRNA expression cassette as the primary
source of instability (Fig. 1g). Applying the same principle of
functional redundancy, we combined the groL-2 and ile-2 gRNA
expression cassettes onto one plasmid and achieved aTcdependent cell death below the limit of detection after 1.5 h
and a fraction viable below 10−6.6 (Fig. 1h). However, this initial
2-gRNA kill switch caused signiﬁcant cell death even in the
absence of aTc, limiting the therapeutic potential of the strain. To
optimize gRNA expression and minimize leaky killing, we
simultaneously mutagenized the -35 sites of the two gRNA Ptet
promoters and assayed colonies from the library (Supplementary
Fig. 1c, d). We isolated one 2-gRNA kill switch that maintained
full killing in the presence of aTc without leaky killing in the
absence of aTc (Fig. 1h). The optimized 2-gRNA kill switch
achieved a fraction viable of less than 10−8.6, surpassing the
killing efﬁciency of 10−8 recommended by the NIH Ofﬁce of
Biotechnology Activities38. The optimized kill switch also
displayed an improved aTc sensitivity relative to the single ile-2
gRNA kill switch (Supplementary Fig. 1e).
Eliminating the reliance on antibiotics for efﬁcient killing.
When the antibiotic (ABX) used to maintain the gRNA expression plasmid was removed from selection plates, we found the
killing efﬁciencies of both 2-gRNA kill switches to be severely
reduced due to loss of the gRNA plasmid during replication
(Fig. 2a, Supplementary Fig. 2a). To enable stability of the kill
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Fig. 2 Eliminating the reliance on antibiotics for efﬁcient killing. a–c System schematics and log10 CFU values for the following kill switch strains:
a optimized 2-gRNA circuit, which has four genome-integrated Ptet-cas9 expression cassettes (X4) and optimized groL-2 and ile-2 Ptet-gRNA expression
cassettes, b ABX-independent 2-gRNA circuit, which has four genome-integrated Ptet-cas9 expression cassettes (X4), optimized groL-2 and ile-2 PtetgRNA expression cassettes, and an unoptimized constitutive infA expression cassette to complement a genomic infA knockout, and c CRISPRks, which has
four genome-integrated Ptet-cas9 expression cassettes (X4), optimized groL-2, ile-2, and rrs-2 Ptet-gRNA expression cassettes, and an optimized
constitutive infA expression cassette to complement a genomic infA knockout. Exponential phase cells for each strain were induced with 0 and 500 ng/mL
aTc for 1.5 h (a), and 1.5 or 3 h (b and c) in LB with and without spectinomycin. CFUs were determined by plating onto LB agar with and/or without
spectinomycin. Differences between the circuit in a and the circuits in b and c are highlighted in the construct schematics in red. gRNA, tetR, and infA
cassettes are located on the same plasmid (connected lines), while cas9 is located exclusively in the genome. ‘Both’ denotes whether antibiotics were
present in both the liquid and solid phase media. d aTc-inducible killing transfer curve for the CRISPRks strain after 3 h of induction in LB without antibiotics.
Points represent experimental data while the line represents the ﬁtted curve. e Long-term stability assessment of the CRISPRks strain. Each day for 28 days,
three replicates of the strain were diluted 250X into fresh LB without antibiotics and grown for 24 h. Every 3–4 days, exponential phase cells were induced
with 0 and 500 ng/mL aTc for 3 h and plated on LB agar without antibiotics for CFU quantiﬁcation. f Log10 Fraction Viable of the CRISPRks strain in
response to 500 ng/mL aTc in M9+0.4% glucose (poor), M9+0.4% glucose+0.2% casamino acids (intermediate), and LB (rich). g Correlation between
generation time and fraction viable. Fraction viable values of <−8 or <−9 had no colonies obtained from cultures receiving aTc. Values and error bars are
the average and standard deviation of biological triplicate, respectively. See also Supplementary Figs. 2, 3 and Supplementary Table 1. Source data are
provided as a Source Data ﬁle.

NATURE COMMUNICATIONS | (2022)13:672 | https://doi.org/10.1038/s41467-022-28163-5 | www.nature.com/naturecommunications

5

ARTICLE

NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-022-28163-5

switch plasmid constructs in the absence of antibiotics, we
implemented a modiﬁed version of a previously described ABXfree plasmid maintenance method39,40. We expressed the essential gene infA (required for initiation of protein synthesis) using
an intermediate strength constitutive promoter on the gRNA
plasmid and knocked it out of the genome of the four Ptet-cas9
integration strain. With this system, EcN needs to maintain the
plasmid to provide InfA and survive. The antibiotic resistance
gene was not removed from the plasmid to allow for CFU
quantiﬁcation in future experiments using mixed strains.
Expressing InfA on the gRNA plasmid eliminated the dependence
on ABX but lowered the efﬁciency of the kill switches (Fig. 2b,
Supplementary Fig. 2b).
Switching a plasmid to InfA-based selection has been shown to
affect plasmid copy number39. We therefore improved the
efﬁciency of the ABX-independent 2-gRNA kill switches using
two methods: increasing gRNA expression by adding an rrs-2
gRNA expression cassette library and tuning the strength of the
constitutive infA cassette. We performed both optimization
methods independently for both the ABX-independent initial
2-gRNA and optimized 2-gRNA kill switches (Supplementary
Fig. 2c–f). Both methods improved kill switch efﬁciency but failed
to restore complete killing. However, when we incorporated a
third gRNA expression cassette into the InfA-optimized,
optimized 2-gRNA kill switch, we obtained two variants that
achieved complete killing in the presence of aTc with uninhibited
growth in the absence of aTc (Supplementary Fig. 3a, b). To
identify the superior CRISPRks variant, we assayed each for their
aTc-response time, aTc-sensitivity, and long-term stability
(Fig. 2c, Supplementary Fig. 3c–f). Both variants were inactivated
at similarly low rates, with a small population of non-functional
cells appearing after 14 days (112 generations) of growth in vitro.
However, the Mut14 variant displayed a signiﬁcantly better
response time, aTc sensitivity, and long-term killing efﬁciency.
The Mut14 CRISPRks achieved complete killing by 3 h of aTc
induction, responded to aTc with a half-maximal concentration
of 21 ng/mL, and displayed highly stable killing over 28 days of
growth (Fig. 2c–e). In addition, the kill switch reliably achieved
complete killing of EcN in diverse nutrient conditions, with a
linear correlation between generation time and log fraction viable
at 1 h (Fig. 2f, g).
Complete killing is achieved by the CRISPRks in vivo after
knocking out key components of the SOS response and providing intra-niche competition. Having demonstrated the
dependence of the kill switch on growth conditions, we next sought
to predict kill switch efﬁcacy in vivo. We developed an in vitro
assay that more closely mirrors the gut, a complex environment
with lower levels of oxygen, nutrients, and mixing than standard
in vitro conditions. When induced with aTc in minimal media,
micro-aerobically, and without shaking, the CRISPRks (circuit
schematic in Fig. 2c) achieved a fraction viable of 10−3.3 after 24 h
of induction (Fig. 3a). After induction, we detected a large fraction
of surviving colonies with kill switch inactivation (Fig. 3b). By 48 h
of induction, the CRISPRks monoculture had rebounded to preinduction levels (Fig. 3a). We hypothesized that supplementing the
assay with microbes that ﬁll the same niche as the CRISPRks strain
could prevent the rapid regrowth of escape mutants and maximize
killing efﬁciency31. We introduced competition into the assay by
incubating the spectinomycin-resistant CRISPRks strain at a 1:1
ratio with a chloramphenicol-resistant control strain. In this mixture, the CRISPRks strain achieved an improved fraction viable of
10−4.2 after 24 h of aTc induction (Fig. 3a, Supplementary Fig. 4a).
Although a population of the 1:1 consortium cells with nonfunctional kill switches was detected among the colonies that
6

survived aTc induction, it was signiﬁcantly smaller than the
population detected from the CRISPRks monocultures (Fig. 3b).
Importantly, the fraction viable remained stable over the course of
the experiment, suggesting that intra-niche competition is important to prevent the repopulation of escape mutants.
CRISPRks escape mutants were observed in the assay
emulating in vivo conditions but not when tested under more
optimal conditions (Fig. 2f), suggesting that the mutations
accumulated de novo during the assay rather than existed in
the inoculum population. Single DNA DSBs, as induced by
CRISPR-Cas9, have been shown to strongly induce the SOS
response in E. coli41,42. This response increases the mutation rate
of the cell through the expression of recombinase genes, including
recA, and diverse error-prone DNA polymerase genes, including
polB, dinB, and umuDC. Thus, we hypothesized that a nutrientand growth-limited environment, which have been shown to
reduce per-cell-protein production43, reduces expression of the
kill switch, impairing the DNA-cleavage rate and allowing the
survival of daughter cells with an induced SOS response and
elevated kill switch inactivation rate. To reduce SOS-responsemediated DNA mutagenesis, we knocked out recA, polB, dinB,
and umuDC (Δrpdu) from the CRISPRks strain. The CRISPRks
Δrpdu kill switch maintained complete killing in optimal growth
conditions (Supplementary Fig. 4b). In an assay emulating in vivo
conditions, the CRISPRks Δrpdu strain achieved a similar
fraction viable as the CRISPRks strain in the absence of
competition (Fig. 3a). However, CRISPRks Δrpdu had a
signiﬁcantly smaller population of non-functional survivors after
24 h of induction, indicating a reduced rate of inactivation, but
with a similar mutation proﬁle (Fig. 3b, c). Most mutations for
both strains were in the promoters of the Ptet-cas9 and Ptet-gRNA
expression cassettes. No mutations were identiﬁed in the infA
cassette or the gRNA target sites. Strikingly, in the presence of
competition from the control strain, CRISPRks Δrpdu cells were
eliminated from the culture by 72 h of aTc induction (Fig. 3a,
Supplementary Fig. 4a). Using the same assay, we found that the
CRISPRks Δrpdu strain was able to be eliminated from the
culture at control:kill switch ratios as low as 1:1000 (Supplementary Fig. 4c). This is important because it suggests the mitigation
of kill switch escape afforded by intra-niche competition is robust
against stochastic variation in sample preparation and colonization efﬁciencies of the two strains; further, a lower proportion of
control relative to engineered probiotic would help maximize
therapeutic potential. Both the CRISPRks and CRISPRks Δrpdu
strains showed similar long-term killing efﬁciencies, kill switch
inactivation rates, and mutation patterns in optimal growth
conditions (Fig. 4d–f). As such, while the Δrpdu knockouts
signiﬁcantly reduce induction-dependent kill switch inactivation,
they have no impact on the mutation rate during normal DNA
replication.
We then tested the efﬁcacy of the CRISPRks and CRISPRks
Δrpdu strains in vivo. C57BL/6 mice were treated with
streptomycin to enable EcN colonization44 (Fig. 3d). 24 h later,
108 CFU of kill switch or control EcN, with or without the Δrpdu
knockouts, were delivered to mice by oral gavage. 24 hours after
EcN gavage, mice were switched to aTc treatment water (105 ng/
mL aTc + 5% sucrose) or control water (5% sucrose) ad libitum,
and fecal samples were collected longitudinally (Fig. 3d). While
both kill switch strains demonstrated signiﬁcant killing activity
in vivo, the CRISPRks Δrpdu strain exhibited improved killing
efﬁcacy with a 4-log reduction in fecal titers after 24 hours of aTc
treatment, compared to a 1-log reduction for the CRISPRks strain
at the same timepoint (Fig. 3e, f). In addition, as observed in vitro
(Fig. 3b), the Δrpdu knockouts mitigated the incidence of escape
mutants; fewer CRISPRks Δrpdu isolates (57 ± 37% versus
100 ± 0%) recovered from stool at the 24-hour timepoint
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Fig. 3 Complete killing is achieved by the CRISPRks in vivo after knocking out key components of the SOS response and providing intra-niche
competition. a Log10 Fraction Viable of the CRISPRks and CRISPRks Δrpdu kill switch strains when incubated alone or at a 1:1 ratio with the no gRNA
control. Cells were cultured anaerobically at 37 °C without shaking in M9+0.4% glucose and induced with 0 or 500 ng/mL aTc. Fraction viable values of
<-8 had no colonies obtained from cultures receiving aTc. Values and error bars are the average and standard deviation of biological triplicate, respectively.
b Percent of cells that survived 24 h of aTc induction with non-functional kill switches. 24 colonies (8 from each replicate) of each condition were tested for
functionality. Values and error bars are the average and standard deviation, respectively. c Sequencing results from 24 CRISPRks and 24 CRISPRks Δrpdu
survivors (8 from each replicate) from a with non-functional ile-2 kill switches. The fraction mutated is the fraction of total sequenced cassettes that
contained a mutation. Values and error bars are the average and standard deviation, respectively. d Schematic for testing the kill switches in vivo. 24 h after
a streptomycin treatment, 108 CFUs of CRISPRks or CRISPRks Δrpdu were gavaged into C57BL/6 mice. 24 h after gavage, mice receiving each kill switch
strain were split into two groups. One group received control water (5% sucrose) and the other group received aTc treatment water (105 ng/mL aTc + 5%
sucrose). Fecal samples were collected 0, 6, 24, and 72 h after gavage for CFU quantiﬁcation. e, f Log10 CFUs/mg feces of e CRISPRks or f CRISPRks Δrpdu
strains from mice receiving control water or aTc treatment water. Points are the average of two technical replicates. Lines and error bars are the average
and standard error from 6 (e) or 4 (f) mice across two cages, respectively. g Percent of CRISPRks and CRISPRks Δrpdu cells that survived aTc treatment
with non-functional kill switches. To assay for kill switch functionality, exponential phase cells were induced with 0 and 500 ng/mL aTc for 3 h and the
absorbance at 600 nm quantiﬁed. Induced to uninduced absorbance ratios within three standard deviations of the no gRNA control strain were deemed
non-functional. 24 colonies (12 from each cage) at each timepoint were tested for functionality. Values and error bars are the average and standard
deviation, respectively. h Schematic for testing control and kill switch co-gavage in vivo. 72 h after a streptomycin treatment, 108 CFUs of a 1:1 ratio mixture
of the no gRNA control strain and CRISPRks Δrpdu were gavaged into C57BL/6 mice. 24 h after gavage, mice receiving each kill switch strain were split
into two groups. One group received control water (5% sucrose) and the other group received aTc treatment water (105 ng/mL aTc + 5% sucrose). Fecal
samples were collected 0, 6, 24, and 48 h after gavage for CFU quantiﬁcation. At the conclusion of the experiment (192 h), mice were sacriﬁced and cecal
contents were collected for CFU quantiﬁcation. i, j Log10 CFUs/mg feces (i) or cecal contents (j) of CRISPRks Δrpdu from mice receiving a 1:1 ratio mixture
of CRISPRks Δrpdu and the no gRNA control strain. Points are the average of two technical replicates. Cecal contents were sampled 8 days after gavage.
Lines and error bars are the average and standard error from 4 mice across two cages, respectively. k Percent of CRISPRks Δrpdu cells that survived aTc
treatment with non-functional kill switches when gavaged alone or in a 1:1 ratio mixture with the no gRNA control strain. 24 colonies (12 from each cage) at
each timepoint were tested for functionality. Statistical comparisons were performed using two-tailed unpaired t-tests (b and c) or two-tailed mixed model
ANOVA with Sidak’s multiple comparisons (e–g, i, and j), (*P < 0.05; **P < 0.01; ***P < 0.001). See also Supplementary Figs. 4 and 5. Source data with
p-values are provided as a Source Data ﬁle.

exhibited loss of kill switch activity in follow-up in vitro assays
(Fig. 3g).
CRISPRks-mediated reduction of EcN titers in vivo was
transient even with the Δrpdu knockouts. Fecal kill switch titers
in aTc-treated mice approached that of mice given control water
by 72 hours of treatment (Fig. 3e, f). At this timepoint, 100% of
recovered kill switch isolates from aTc-treated mice demonstrated
loss-of-function in follow-up in vitro assays (Fig. 3g), indicating a
bloom of an escape mutant population in vivo. We additionally
observed that fecal titers of the control strains were low on
average and highly variable at treatment baseline (Supplementary
Fig. 4g, h). In contrast, fecal titers of CRISPRks strains
consistently reached 5-6 logs at treatment baseline (Fig. 3e, f).
We hypothesized that the spectinomycin-resistant kill switch
strains were cross-resistant to the streptomycin used for knockdown of the native microbiota, a phenotype not afforded to the
chloramphenicol-resistant control strains. Indeed, we observed
that baseline fecal titers of chloramphenicol-resistant EcN were
dependent on the length of the interval between streptomycin and
EcN gavage, while those of an isogenic spectinomycin-resistant
strain of EcN were not (Supplementary Fig. 5a, b). We sought to
optimize the microbiota knockdown protocol to consistently
achieve equal baseline titers of the control and CRISPRks strains,
either by extending the interval between streptomycin treatment
and EcN gavage or through use of an alternative antibiotic, and
determined that waiting 72 h after streptomycin treatment
enables equivalent baseline titers of chloramphenicol-resistant
and spectinomycin-resistant EcN (Supplementary Fig. 5b). In
contrast, omission of any antibiotic treatment resulted in
undetectable levels of either EcN strain (Supplementary Fig. 5c),
indicating a failure to colonize, while treatment with
carbenicillin45 48 hours before EcN gavage resulted in low and
variable titers of both EcN strains (Supplementary Fig. 5d).
We therefore carried out another experiment in mice with the
CRISPRks Δrpdu and control Δrpdu strains with a 72 h interval
between streptomycin and EcN gavage. Motivated by the
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hypothesis that intra-niche competition by an isogenic non-kill
switch EcN strain can support eradication of the kill switch EcN
population, we included an additional arm in which we cogavaged the kill switch and control strains at a 1:1 ratio (Fig. 3h).
This is an attractive approach when the goal is eradication of a
speciﬁc population of engineered microbes, rather than a
probiotic species itself, from the gut. Using the 72 h interval, we
were able to achieve equivalent baseline titers of spectinomycinresistant CRISPRks Δrpdu and chloramphenicol-resistant control
Δrpdu EcN (Fig. 3i, Supplementary Fig. 5e, f). Remarkably, when
CRISPRks Δrpdu EcN was co-gavaged with control Δrpdu EcN,
the CRISPRks Δrpdu strain was no longer detectable in stool by
48 hours of aTc treatment (Fig. 3i). Except for a single colony
observed after plating undiluted fecal homogenate, the CRISPRks
Δrpdu strain remained undetectable in cecal contents after 8 days
of aTc treatment, demonstrating almost complete eradication of
the engineered microbe from the mice (Fig. 3j). In contrast, titers
of control Δrpdu EcN in the same mice remained stable over the
course of aTc treatment, as did titers of both strains (similarly cogavaged) in mice treated with control water (Fig. 3i). Correspondingly, we were still able to detect EcN in the ceca of these
mice at sacriﬁce, with cecal titers not signiﬁcantly different
between the control strain in either treatment arm and the
CRISPRks Δrpdu strain in the control water arm (Fig. 3j). After
24 hours of aTc treatment in vivo, 100% of CRISPRks Δrpdu
isolates recovered from mice colonized with only this strain
exhibited loss of kill switch function in vitro, while no loss of
function was observed in isolates of the same strain from cogavaged mice (Fig. 3k). These data indicate that a combined
approach of kill switch induction and intra-niche competition can
mitigate the emergence of escape mutant populations in vivo.
Development of a 2-input CRISPRks that responds to both aTc
and reduced temperatures. Several temperature sensors have
been characterized in other strains of E. coli30,46,47. Of these
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degradation tag library onto TetR. d Long-term stability of the optimized 2-input kill switch. Each day for 28 days, three replicates of the strain were diluted
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overnight at 37 °C and for 7 days at 30 °C for CFU quantiﬁcation. Fraction viable values of <-7 had no colonies obtained from cultures receiving aTc. e Cell
death transfer curve with respect to temperature for the no gRNA control and the optimized 2-input kill switch. Exponential phase cells were incubated in a
thermocycler for 5 h at a range of temperatures: 30, 30.6, 31.6, 32.8, 34.4, 35.6, 36.4, and 37 °C. Points represent experimental data while the line
represents the ﬁtted curve. Values and error bars are the average and standard deviation of biological triplicate, respectively. See also Supplementary Fig. 6
and Supplementary Table 1. Source data are provided as a Source Data ﬁle.

sensors, the PtlpA promoter with a modiﬁed TlpA regulator
protein from Salmonella demonstrated the highest fold-change in
expression in response to a temperature reduction. TlpA is a
transcriptional regulator that assembles into homodimers and
represses transcription from the PtlpA promoter at low
temperatures48. At high temperatures, the dimers are unable to
form, allowing transcription. To characterize the sensor in EcN,
we obtained the PtlpA-tlpA temperature sensing system from
Salmonella typhimurium SL1344 genomic DNA and used it to
drive expression of a green ﬂuorescent protein (GFP) reporter.
The wild-type TlpA sensor induced GFP expression with a half
maximal ﬂuorescence at 43.4 °C, signiﬁcantly above our desired
range (Supplementary Fig. 6a). We next inserted ﬁve amino acid
substitutions identiﬁed by Pirner et al. to generate the modiﬁed
TlpA sensor, TlpA*30. As previously demonstrated, the mutations
shifted the half maximal ﬂuorescence to a temperature of 35.6 °C
(Supplementary Fig. 6b). Expression of GFP was 97% repressed at
a temperature of 34 °C compared to 37 °C.

To make a 2-input CRISPRks that induces cell death in
response to both aTc and a temperature downshift (i.e., an OR
gate), we replaced the constitutive promoter driving TetR
expression with the PtlpA-tlpA* temperature sensor (Fig. 4a).
With this design, TetR expression is inhibited by TlpA* at low
temperatures (<33 °C), de-repressing expression of the kill switch.
At 37 °C, TetR is expressed, and the kill switch remains sensitive
to aTc. This initial 2-input CRISPRks achieved complete cell
death in response to aTc, but only a modest reduction in fraction
viable (10−1.7) at 30 °C (Fig. 4b). We hypothesized that the
temperature-dependent response was poor because the circuit
inhibits new TetR production but not the activity of TetR already
in the cell. Numerous cell divisions may be required to dilute
cytosolic TetR concentrations below the threshold for kill switch
induction. To test this hypothesis, we performed a liquid-phase,
temperature-response kill switch assay using a range of initial
dilution factors, where larger starting dilutions would allow more
growth and smaller per-cell TetR concentrations. The killing
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efﬁciency was directly correlated to the dilution factor, conﬁrming the dependence on cell divisions for kill switch activation
(Supplementary Fig. 6c). To improve the response to temperature, we sought to uncouple TetR removal from cell growth. We
simultaneously optimized the expression level and stability of
TetR by inserting a ribosome binding site (RBS) library and a
C-terminal SsrA degradation tag library, respectively (Fig. 4c).
We tested over 500 2-input CRISPRks Δrpdu variants from the
combined RBS and degradation tag library and identiﬁed eight
that achieved efﬁcient cell death at 30 °C with minimal growth
inhibition at 37 °C (Supplementary Fig. 6d). To select the best kill
switch, we assayed select variants for long-term stability and
temperature sensitivity (Supplementary Fig. 6e, f). The ﬁnal
selected variant was highly stable over 28 days of growth (Fig. 4d)
and demonstrated an ultrasensitive response to temperature, with
no killing at 33-37 °C and strong killing at temperatures less than
32 °C (Fig. 4e).
The 2-input CRISPRks efﬁciently kills EcN in response to both
aTc treatment and excretion from mice. We next tested the
in vivo efﬁciency of the 2-input CRISPRks Δrpdu strain when
gavaged into streptomycin-treated mice alone, or in co-gavage
with the cognate control strain at a 1:1 ratio (Fig. 5a). In a control
arm, mice were instead singly-gavaged with the control strain as
before. To assay chemical induction of the 2-input kill switch,
24 hours after EcN gavage, mice were switched to aTc treatment
water or control water ad libitum, and fecal samples were collected longitudinally over a week (Fig. 5a). To assay temperature
induction of the 2-input kill switch, collected stool was processed
at both 37 °C and room temperature (22 °C); results from samples
processed at 37 °C reﬂect only within-gut aTc induction of kill
switch activity, while those processed at 22 °C additionally reﬂect
temperature induction of the kill switch after excretion.
When singly-gavaged, aTc induction of the 2-input CRISPRks
Δrpdu strain within mice resulted in a signiﬁcant (3-log)
reduction in fecal titers. However, this response was again
transient over the ﬁrst 48 h of treatment with the kill switch
population rebounding to baseline levels by 72 h and remaining
high in stool on day 7 and in the ceca on day 8 (Supplementary
Fig. 7b, c, top). Temperature induction of the 2-input CRISPRks
Δrpdu strain in stool collected from these mice greatly improved
killing efﬁcacy; we consistently observed 1- to 2-log CFU/mg EcN
in stool from mice that were not induced with aTc, 5-log lower
than control strain titers, indicating that this reduction was driven
by temperature induction alone (Supplementary Fig. 7b, bottom).
When combined with aTc induction in mice, temperature
induction (i.e., post-excretion) further reduced fecal titers such
that we were unable to detect EcN in stool from these mice at the
24- and 48-h timepoints (Supplementary Fig. 7b, bottom).
However, the kill switch population was not completely
eradicated as we were able to detect it in stool on day 7 and in
the ceca on day 8 (Supplementary Fig. 7b, c, bottom).
Interestingly, we also observed greater variability in stool titers
of the control strain in mice treated with aTc compared to control
water, including one mouse in which we were unable to detect
control strain at multiple timepoints (Supplementary Fig. 7a).
This high variability may be due to aTc induction of the Cas9
complex (which the control strain carries despite lacking gRNAs),
leading to decreased in vivo ﬁtness, potentially coupled with a rise
of control strain subpopulations with inactivating mutations (e.g.,
mutations in the Ptet promoter driving Cas9 expression).
Co-gavage of the 2-input CRIPRSks Δrpdu strain with the
control strain, providing intra-niche competition, mitigated the
bloom of an escape mutant population during aTc treatment
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(Fig. 5b, top). This was evidenced by signiﬁcantly lower
(p = 0.0006; mixed model ANOVA) stool and cecal titers of the
kill switch strain in aTc-treated mice compared to control strain
titers in the same mice, or to either strain in mice treated with
control water. Correspondingly, fewer kill switch isolates
recovered from co-gavaged mice exhibited loss of function in
follow-up in vitro kill switch assays compared to isolates from
singly-gavaged mice (29 ± 6% compared to 92 ± 12% on day 3,
and 67 ± 24% compared to 100% by day 7) (Fig. 5c). As in the
single-gavage arm (Supplementary Fig. 7), in samples from cogavaged mice, temperature induction alone of the 2-input kill
switch resulted in high killing efﬁcacy (1-log CFU/mg feces [gray
circles] compared to 4-log CFU/mg for the control strain in the
same mice [white triangles]), but the kill switch population
increased in titer by day 7 (Fig. 5b, bottom). When we sequenced
non-functional isolates, we identiﬁed mutations throughout the
cas9, gRNA, tetR, and tlpA expression cassettes, suggesting the
presence of diverse inactivation mechanisms and that the stability
of the kill switch cannot be easily improved through additional
functional redundances (Fig. 5d). Again, no mutations were
identiﬁed in the infA cassette or the gRNA target sites.
Strikingly, a combination approach, including provision of
intra-niche competition by a competing strain, within-gut
chemical kill switch induction, and temperature kill switch
induction outside the gut, was effective for eradicating the kill
switch population; with these conditions, we were unable to
detect the 2-input CRISPRks strain in stool beginning at the 24hour timepoint and through the end of the experiment, nor in the
ceca on day 8 (Fig. 5b, bottom [red circles]). In addition to plating
directly from stool and ceca to quantify EcN, we used fecal and
cecal samples to inoculate room temperature kinetic growth
assays in rich media as a more sensitive measure of temperatureinduced biocontainment, where any EcN population that may
have been below the limit of detection of the direct plating assays
has the opportunity to amplify (Fig. 5e, f, Supplementary Fig. 7d,
e). In line with the direct plating results, while on days 7 and 8
(cecal timepoint), we observed some growth of the 2-input
CRISPRks Δrpdu strain in cultures inoculated from mice not
treated with aTc (gray lines), we observed no growth over
24 hours of the kill switch strain in cultures inoculated from mice
that had been treated with aTc (red lines, Fig. 5e); with the
exception of an average of 101.4 kill switch colonies observed at
the 72-hour timepoint, plating from the kinetic growth assays at
their termination to quantify CFUs conﬁrmed this result (Fig. 5f).
In contrast, in growth assays inoculated from mice treated with
aTc in the single-gavage arms, we observed no signiﬁcant
difference in titers of 2-input kill switch strains and control
strains (Supplementary Fig. 7d, e). These data indicate that intraniche strain competition is required to mitigate aTc-mediated
selection for kill switch mutants that escape both chemical and
temperature induction modalities.
It is important that biocontainment systems minimally impact
the protein production capability and therapeutic potential of the
engineered microbe. To determine how the kill switches designed
here impact protein expression in EcN, we quantiﬁed the expression
of a constitutively expressed GFP reporter using both a genomeintegrated and plasmid-based cassette. Both the CRISPRks Δrpdu
strain and the 2-input CRISPRks Δrpdu strain achieved GFP
expression levels equivalent to wild-type EcN and the no gRNA
control strain (Supplementary Fig. 8). This trend remained true for
both genome-integrated and plasmid-based expression methods. As
such, the aTc-responsive CRISPRks Δrpdu kill switch and the aTcand temperature-responsive 2-input CRISPRks Δrpdu kill switch
can be effectively applied towards the biocontainment of engineered
therapeutic and diagnostic microbes.
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Discussion
Robust control of the viability of engineered probiotics is essential
for the host safety and the environmental protection. The aTconly and 2-input CRISPRks strains developed here allow the
growth of EcN to be tightly controlled during in vivo applications.

2-input CRISPRks

Expression Cassette

To develop the two CRISPRks strains, we explored a variety of
methods for optimizing genetic stability, including incorporating
multiple functionally redundant Cas9 and gRNA expression
cassettes (Figs. 1 and 2), eliminating reliance on antibiotics for kill
switch maintenance (Fig. 2), knocking out key SOS response
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Fig. 5 The 2-input CRISPRks efﬁciently kills EcN in response to both aTc treatment and excretion from mice. a Schematic for testing co-gavage of the
control strain and 2-input CRISPRks in vivo. 72 h after a streptomycin treatment, 108 CFUs of a 1:1 ratio mixture of the no gRNA control strain and 2-input
CRISPRks were gavaged into C57BL/6 mice. 24 h after gavage, mice were split into two groups. One group received control water (5% sucrose) and the
other group received aTc treatment water (105 ng/mL aTc + 5% sucrose). Fecal samples were collected 0, 24, 48, 72, and 168 h after gavage for CFU
quantiﬁcation. At the conclusion of the experiment (192 h), mice were sacriﬁced and cecal contents were collected for CFU quantiﬁcation. Fecal and cecal
contents were plated at 37 °C overnight or room temperature (RT) for 48 h. Samples were also incubated in LB broth at RT for 24 h and plated at RT for
48 h for CFU quantiﬁcation. b Log10 CFUs/mg feces (left) or cecal contents (right) of 2-input CRISPRks cells from mice receiving a 1:1 ratio mixture of
2-input CRISPRks and the no gRNA control strain. CFUs were quantiﬁed at 37 °C (top) or RT (bottom). Points are the average of two technical replicates.
Lines and error bars are the average and standard error from 6 mice across two cages, respectively. Statistical comparisons were made between control
water and aTc treatment (top) or control strain and 2-input CRISPRks (bottom). c Percent of 2-input CRISPRks cells that survived aTc treatment or control
water with non-functional kill switches when gavaged alone (from Supplementary Fig. 7b, top) or in a 1:1 ratio mixture of 2-input CRISPRks and the no
gRNA control strain (from Fig. 5b, top). To assay for kill switch functionality, exponential phase cells were induced with 0 and 500 ng/mL aTc for 3 h and
the absorbance at 600 nm quantiﬁed. Induced to uninduced absorbance ratios within three standard deviations of the no gRNA control strain were deemed
non-functional. 24 colonies (12 from each cage) at each timepoint were tested for functionality through an in vitro aTc-response assay. d Sequencing
results from 24 2-input CRISPRks survivors from Fig. 5b, top with non-functional kill switches. The fraction mutated is the fraction of total sequenced
cassettes that contained a mutation. Mutations in the PtlpA promoter are counted as mutations in both the tetR and tlpA expression cassettes. e RT growth
assays for control and 2-input CRISPRks cells obtained from fecal or cecal samples at different timepoints in Fig. 5b. f CFUs of control and 2-input CRISPRks
cells from Fig. 5e following 24 h of RT growth. Points are the average of two technical replicates. Values and error bars are the average and standard error
from 6 mice across two cages, respectively. Statistical comparisons were performed using two-tailed mixed model ANOVA (c) or two-tailed mixed model
ANOVA with Sidak’s multiple comparisons (b and f) (*P < 0.05; **P < 0.01; ***P < 0.001, ****P < 0.0001). See also Supplementary Fig. 7. Source data with
p-values are provided as a Source Data ﬁle.

genes involved in DNA mutagenesis (Fig. 3), providing intraniche competition (Figs. 3 and 5), and combining two layered
methods of viability control (Figs. 4 and 5).
In this work, we addressed two routes of DNA mutagenesis that
contributed to kill switch instability (Fig. 6a). First, we mitigated
stochastic inactivation of kill switch constructs resulting from the
natural and slow accumulation of errors that occurs during DNA
replication49,50. Introduction of functionally redundant Cas9 and
gRNA expression cassettes reduced the kill switch inactivation rate
due to these processes, enabling kill switch stability for at least
28 days of growth. However, we continued to detect inactivated
CRISPRks variants after about 14 days of growth (Supplementary
Fig. 4d–f). The rate of evolution can potentially be further reduced
by optimizing the metabolic burden required to maintain the
circuit51, improving the accuracy of DNA replication52, and
knocking out transposable elements53,54. The second route of kill
switch inactivation involved SOS-mediated DNA mutagenesis in
response to the DSBs caused by Cas9 (Fig. 6a). Escape mutants of
our CRISPRks strain only arose via this process when tested
in vivo or with in vivo-like conditions where resources and growth
are limited55. In these conditions, limited induction of the kill
switch may lead to incomplete cleavage of the multi-copy replicating chromosome. Low levels of DSBs per cell would allow
daughter cells to survive with intact copies of the chromosome,
but with an activated SOS response and an elevated rate of DNA
mutagenesis. Expression of a genome-integrated GFP reporter is
signiﬁcantly weaker in minimal medium compared to rich medium, suggesting lower Cas9 expression levels in nutrient-poor
conditions (Supplementary Fig. 8). In addition, even single double
strand breaks have been shown to strongly induce the SOS
response41. We successfully reduced SOS-mediated inactivation
through the Δrpdu knockouts, allowing for complete killing of the
CRISPRks strain in growth-limited conditions. Knocking out
alternative recombinases with known low levels of activity may
further improve the stability of the 2-input CRISPRks in vivo56. In
addition, our current gRNAs target the chromosome near the
origin of replication where growth-dependent copy numbers
would be highest (Fig. 1b). Utilizing gRNAs that instead target the
region where growth-dependent chromosomal copy numbers are
lower may decrease the number of daughter cells that escape kill
switch induction with intact genomes and reduce the potential for
SOS-mediated kill switch inactivation.
12

Mutations in the Ptet-cas9 and Ptet-gRNA cassettes each contributed to ~45% of the total observed mutations, highlighting the
importance of functionally redundant expression cassettes
(Fig. 6b). Importantly, the Ptet promoters within these cassettes
were the primary source of instability. The Ptet promoter used in
these kill switches contains two identical 19 bp tet operator sites.
Over 50% of the total observed mutations were 25 bp deletions
including one of these operators and most of the -35 site (Fig. 6c).
These deletions can occur through RecA-dependent homologous
recombination, or RecA-independent rearrangement of tandem
repeat sequences by replication slippage, sister-chromosome
exchange-associated slippage, and single-strand annealing50.
Replacing the Ptet promoters with engineered variants that have
only one tet operator site or operator sites with lower sequence
identity, or using alternative chemical-inducible promoters lacking internal homology, may further improve the stability of the
kill switches.
Biocontainment of genetically engineered organisms must not
neglect biocontainment of the corresponding recombinant
nucleic acids, due to the possibility of horizontal gene transfer
(e.g., antibiotic resistance genes, especially as mediated by
plasmids)57,58. Our kill switch design mitigates this possibility in
that the only plasmid-borne elements include the Tet repressor,
which does not alone confer antibiotic resistance, and the gRNAs,
which carry inherent speciﬁcity to the EcN genome and whose
transcription should have no cleaving effect in the absence of the
Cas9 cassette. As such, the incorporation of the infA plasmidmaintenance system served to both improve stability of the kill
switch and reduce the risk of antibiotic resistance gene dissemination. We included plasmid-borne spectinomycin and
chloramphenicol resistance genes to selectively distinguish our
control and CRISPRks strains in co-culture and co-gavage
experiments; clinical iterations of the kill switch strains for
practical applications would omit these selective markers.
Inspired by the competitive inter-strain exclusion properties
observed in gut pathogens59 and commensals alike31,60, we
hypothesized genetic approaches for mitigating kill switch escape
could be complemented at the population level by external
competitive pressure. With the goal of eliminating a speciﬁc
subpopulation of engineered microbes and not a probiotic species
itself from the gut, we provided both CRISPRks EcN and control
EcN in our animal models, and demonstrated that kill switch
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Fig. 6 Summary of sequencing results from non-functional kill switches and potential mechanisms of circuit inactivation. a Potential mechanisms of kill
switch inactivation and cell survival. DSB, double-strand break. b Classiﬁcations of the observed mutations in Ptet-cas9, Ptet-gRNA, tetR, and tlpA expression
cassettes. Source data are provided as a Source Data ﬁle. c Sequence of the most commonly observed inactivation mutation in the utilized Ptet promoters.

induction in synergy with competitive exclusion enabled virtually
complete eradication of the kill switch population. Co- or preadministration of a wild-type probiotic strain in clinical applications of engineered probiotics could help prime the gut for
induced elimination of the engineered probiotic. However, ways
to ensure the stability of both populations prior to kill switch
induction must be further investigated.
The performance of the kill switches could be further improved
by addition of an orthogonal kill switch mechanism, an approach
that has recently been demonstrated to have a multiplicative
effect on efﬁcacy18. In the absence of aTc exposure in the gut (i.e.,
induction only with temperature upon excretion), there was an
increasing incidence over time of biocontainment failure for the
2-input CRISPRks (Fig. 5b, bottom), suggesting that the strain
requires both induction modalities to perform robustly. Indeed,

the 2-input CRISPRks also did not achieve full efﬁcacy in vitro
when induced with temperature alone (Fig. 4b), in contrast to the
single-input kill switch when induced with aTc in vitro (Fig. 2c),
indicating that PtlpA-driven expression of tetR may be leaky even
at low temperatures or that the TetR degradation rate is not
sufﬁciently high to robustly induce kill switch activation. Because
the temperature- and aTc-driven induction feed into the same kill
switch mechanism, the combination of both inputs does not
result in a synergistic increase in efﬁcacy. Similarly, induction
with both temperature and aTc in the context of intra-niche
competition led to no detectable growth after direct plating of
feces (approximately 2% of the entire fecal sample at the 1X
dilution), nor after inoculating 24 h growth assays at room temperature to allow any putative escape mutants to amplify; the
exception was at the 72 h timepoint, where after 24 h of growth in
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rich media, we observed a mean 583 CFU/mL of the 2-input
CRISPRks (Fig. 5f). With a room temperature doubling time of
115 min estimated from control strain titers from the same mice
at the same timepoint, this implies a baseline CRISPRks titer of
0.1 CFU/mL, or approximately 100 CFU in the entire fecal
sample given our inoculation scheme. This was not captured
when plating directly from feces (Fig. 5b, bottom), highlighting
the importance of survival assay sensitivity in the development of
kill switches. Escape events such as this could also be mitigated by
addition of an orthogonal kill switch circuit, in addition to further
optimization of the tlpA and tetR cassettes.
In summary, we developed CRISPR-based kill switches in EcN
to create a safe probiotic chassis for future biomedical technologies. These kill switches allow EcN to proliferate under normal
gut conditions and initiate cell death in response to oral consumption of an inducer and excretion from the body. We have
demonstrated a kill switch approach to on-demand selective
removal of engineered microbes from the gut. We also explored
diverse methods for improving the stability of the kill switches
and minimized key mechanisms of kill switch inactivation. The
engineered kill switches apply genetic parts (CRISPR/Cas9 and
TetR/Ptet) that have been shown to be functional in diverse
microbes32–34. As such, similar kill switches can be engineered for
a larger panel of probiotic microbes. Furthermore, the temperature sensing module can be replaced with sensors for alternative
environmental conditions46 and chemicals61–63 to create 2-input
kill switches for novel applications. These microbial biocontainment tools will facilitate the creation of living therapeutics or
other microbes for environmental applications that are more
robust, predictable, and controllable, which is critical for both
regulatory approval and public acceptance of genetically modiﬁed
organisms.
Methods
Experimental model and subject details. All in vitro experiments were performed in compliance with the Washington University in Saint Louis Institutional
Biological & Chemical (IBC) Safety Committee. All plasmids were assembled in
and puriﬁed from E. coli DH10B. Puriﬁed plasmids were subsequently transferred
to and tested in wild-type or engineered E. coli Nissle 1917 variants lacking the two
native plasmids, pMUT1 and pMUT2.
All mouse experiments were approved by the Washington University in Saint
Louis School of Medicine Institutional Animal Care and Use Committee (Protocol
number: 21-0160), and performed in AAALAC-accredited facilities in accordance
with the National Institutes of Health guide for the case and use of laboratory animals.
All mouse experiments were performed in female 8-week old C57BL/6 mice
(Jackson Labs C57BL/6 J, RRID:IMSR_JAX:000664). Mice were housed in a speciﬁc
pathogen free barrier facility maintained by WUSM DCM at 30-70% humidity and
68–79 °F under a 12:12 hour light:dark cycle. Mice were provided feed (Purina
Conventional Mouse Diet (JL Rat/Mouse 6 F Auto) #5K67) and water ad libitum.
Mice were co-housed with up to 5 mice per cage, and at least 2 cages per
experimental arm to account for cage effects.
Oral gavage of mice was performed using 18ga x 38 mm plastic feeding tubes
(FTP-18-38, Instech). To ablate the native microbiome prior to EcN colonization,
each mouse was administered 20 mg streptomycin sulfate salt (S6501, SigmaAldrich) in 100 μL H2O via oral gavage44. Streptomycin treatment of mice, often
used in Salmonella enterica colonization models44, has also been used extensively in
colonization models for commensal and pathogenic strains of Escherichia
coli13,31,64–68. 24 or 72 hours after streptomycin administration, mice were orally
gavaged with 108 CFU EcN in 100 μL phosphate buffered saline (PBS). To test
alternative microbiome ablation strategies, mice were instead orally gavaged with
6 mg carbenicillin disodium salt (C1389, Sigma-Aldrich) in 100 μL H2O 48 hours
prior to EcN administration45, or left untreated prior to EcN administration.
24 hours after EcN administration, mice were switched from standard drinking
water to aTc treatment water (105 ng/mL aTc + 5% sucrose, ﬁlter sterilized) or
control water (5% sucrose, ﬁlter sterilized), provided ad libitum. Treatment water
and control water were prepared fresh and replaced daily for the duration of each
experiment. Fecal samples were collected at the indicated timepoints. At the end of
each experiment, mice were sacriﬁced through carbon dioxide asphyxiation.
Method details
Plasmids, strains, and growth conditions. All plasmids were designed using SnapGene and assembled in E. coli DH10B using the Gibson Assembly (100 mM Tris14

HCl, 10 mM MgCl2, 0.2 mM dNTPs, 10 mM DTT, 5% PEG-8000, 1 mM NAD+, 4
U/μL Taq DNA ligase, 4 U/mL T5 exonuclease, 25 U/mL Phusion DNA polymerase) or Golden Gate Assembly (1X T4 ligase buffer, 1X Cutsmart buffer, 40 U/
μL T4 ligase, 1 U/μL SapI, 1 U/μL DpnI) methods. Wild-type or engineered EcN
variants were then transformed with the puriﬁed and sequence-veriﬁed plasmids
for kill switch testing. Plasmid DNA was isolated using the PureLink Quick
Plasmid Miniprep Kit (K210011, Invitrogen), and polymerase chain reaction (PCR)
products were extracted from electrophoresis gels using the Zymoclean Gel DNA
Recovery Kit (D4008, ZYMO research). Enzymes were purchased from New
England Biolabs (Ipswich, MA, USA).
To construct engineered EcN variants, we utilized lambda red-mediated
CRISPR-Cas9 recombineering as previously described69. To create knockouts of
speciﬁc genes (Supplementary Table 2), gRNAs for the pgRNA plasmid were
designed using the gRNA designer from Atum (atum.bio) to target the gene of
interest. 60 bp ssDNA oligos were designed with 30 bp arms homologous to the
lagging strand of DNA synthesis ﬂanking the region to be knocked out. For
insertions (Supplementary Table 3), the pgRNA plasmid was similarly constructed.
The dsDNA insert was obtained by constructing a plasmid with the DNA to be
inserted ﬂanked by 500 bp arms homologous to the insertion region. The full
product (both arms and insert DNA) were PCR ampliﬁed and puriﬁed by gel
extraction. EcN harboring pMP11 was then transformed with 100 ng of the
respective pgRNA plasmid and either 1 μM of the ssDNA oligo or 100 ng of the
dsDNA insert to initiate recombination. All sequencing (Supplementary Table 4)
was performed by Genewiz (South Plainﬁeld, NJ, USA). Primers were purchased
from Integrated DNA Technologies (Coralville, IA, USA). All plasmids and parts
constructed and used in this work are summarized in Supplementary Tables 5, 6,
respectively.
Unless otherwise speciﬁed, LB medium was used for culturing. For Figs. 2f, 3a,
Supplementary Fig. 4a, c, M9 minimal medium supplemented with 1 mM MgSO4,
100 μM CaCl2, and 0.4% w/v glucose was used. 0.2% w/v casamino acids was also
added to the M9 minimal medium as speciﬁed. Medium was supplemented with
the following concentrations of antibiotics as necessary: 100 μg/mL ampicillin,
34 μg/mL chloramphenicol, 20 μg/mL kanamycin, 10 μg/mL gentamycin, and
100 μg/mL spectinomycin (Gold Biotechnology, Olivette, MO, USA). Unless
otherwise stated, cultures were incubated at 37 °C with 250 rpm shaking.
Standard kill switch assays. EcN was transformed with kill switch plasmids by
electroporation and plated on LB agar with the relevant antibiotics. Single colonies
were then transferred to 1 mL of LB in 14 mL round bottom tubes (14-959-11B,
Fisher Scientiﬁc) and grown in a shaking incubator at 37 °C and 250 rpm for ~2 h
until exponential phase (OD600 of 0.25-0.50) was reached. To test for aTcinducible cell death, these cultures were diluted to an OD600 of 0.01 in 1 mL fresh
LB medium with the speciﬁed concentrations of aTc28. At the indicated timepoints,
samples were removed from the cultures for viable colony forming unit (CFU)
quantiﬁcation. CFUs were determined by plating 10 μL of serially diluted cultures
onto LB agar with the relevant antibiotics unless otherwise speciﬁed and incubating
at 37 °C overnight. For cultures where no colonies were obtained in the undiluted
sample, 100 μL was also plated to ensure a more accurate quantiﬁcation. The
fraction of viable cells was calculated as the ratio of CFUs obtained from the
induced culture to the number of CFUs obtained from the uninduced culture. To
test for temperature-inducible cell death, the exponential phase cultures were
serially diluted and plated onto two LB agar plates. One plate was incubated at
37 °C overnight while the other plate was incubated at 30 °C for two weeks. For
temperature-sensitive assays, all liquid medium and LB agar plates were preheated
to 37 °C for at least two hours prior to the addition of cells.
Long-term stability kill switch assay. A long-term stability assay was used for
Figs. 2e, 4d, Supplementary Figs. 3e, 6e. On day 1, single colonies were transferred
to 1 mL LB without antibiotics, incubated until an OD600 of 0.25–0.50 was
reached, and diluted to an OD600 of 0.01 for the standard aTc kill switch assay or
directly plated onto LB agar for the standard temperature kill switch assay as
before. The original undiluted cultures were then returned to the shaking incubator
and cultured for an additional ~22 h (24 h of incubation total). After the 24 h
incubation, each culture was diluted 250X into fresh LB without antibiotics and
incubated for an additional 24 h. These daily dilutions were repeated for a total of
28 days. Every 3–4 days, the culture was used for the kill switch assays as described
above. On assay days, culture samples were stored at −80 °C in 15% (v/v) glycerol.
Temperature-sensing transfer curve kill switch assay. For temperature-sensitive
transfer curves, single colonies were then transferred to 1 mL of LB in 14 mL round
bottom tubes and grown in a shaking incubator at 37 °C and 250 rpm for ~2 h until
exponential phase (OD600 of 0.25–0.50) was reached. These cultures were then
diluted to an OD600 of 0.01 in 50 μL of fresh LB medium in PCR tubes and
incubated at the speciﬁed temperatures in a thermocycler for 5 h. CFUs were
determined by plating 10 μL of serially diluted cultures onto LB agar and incubating at 37 °C overnight.
In vitro condition-poor competition kill switch assay. EcN strains with and without
the Δrpdu knockouts were transformed with the no gRNA control and the aTcinducible CRISPRks. Single colonies for each of the four strains were grown overnight
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in 5 mL LB at 37 °C and 250 rpm. The following day, each culture was centrifuged at
3,000 g, the LB supernatant was removed, and the cell pellet was resuspended in 5 mL
M9 + 0.4% glucose. For CRISPRks-only cultures, 1.5 mL of the respective CRISPRks
strain was diluted into two 15 mL conical tube at a ﬁnal volume of 15 mL M9 + 0.4%
glucose. For competitive mixture cultures, 0.75 mL of each CRISPRks strain was also
diluted at a 1:1 ratio with the respective no gRNA control strain (1.5 mL total culture)
into two additional 15 mL conical tubes. One of the two conical tubes in each pair was
induced with 500 ng/mL aTc. Each tube was capped to stop oxygen transfer and
incubated at 37 °C without shaking. Every 24 h for 72 h, the cultures were removed
from the incubator, the CFUs were quantiﬁed, and the cells were diluted 10X into a
new tube with fresh M9 + 0.4% glucose and 500 ng/mL aTc.
Assays of intestinal samples for quantiﬁcation of viable EcN. Fecal samples (and cecal
samples post-sacriﬁce) were collected in pre-weighed sterile 2 mL microtubes, and
weighed again to accurately measure sample mass. Samples were homogenized in
500 μL PBS on a benchtop vortexer (2000 rpm for 3 min), serially diluted in PBS, and
plated on LB agar supplemented with 100 μg/mL spectinomycin dihydrochloride
pentahydrate (S4014, Sigma-Aldrich) to select for spectinomycin-resistant kill switch
strains, and 34 μg/mL chloramphenicol (AC227920250, Acros Organics) to select for
chloramphenicol-resistant control strains. All samples were plated on both chloramphenicol- and spectinomycin-supplemented LB agar plates to conﬁrm no crosscontamination of strains between experimental arms. Dilutions of fecal or cecal
homogenates plated for all experiments spanned 100 to 10−6 (i.e. undiluted homogenate was plated for each sample). CFU/mg sample values were calculated from
enumerated colonies. Two technical replicates per intestinal sample were processed.
For experiments with the single-input CRISPRks (aTc-inducible only) strains,
samples were weighed, resuspended, serially diluted, and plated at room
temperature (22 °C), and plates were incubated overnight at 37 °C prior to colony
enumeration. For experiments with the 2-input CRISPRks (aTc- and temperatureinducible) strains, fecal samples were immediately placed in a pre-warmed
heatblock (37 °C) inside an insulated container. Similarly, to maintain cecal
samples at 37 °C, freshly sacriﬁced mice were kept in a 37 °C incubator until
dissection and collection of cecal contents. Samples were weighed, resuspended,
serially diluted, and plated inside a 37 °C warm room, using pre-warmed PBS and
LB agar plates. After plating, LB plates continued to be incubated at 37 °C
overnight prior to colony enumeration. To assay temperature-dependent induction
of the kill switch, samples were then moved to room temperature (22 °C) and again
plated on spectinomycin- or chloramphenicol-supplemented LB agar plates. Plates
were incubated at 22 °C for 48 h prior to colony enumeration.
To assay biocontainment efﬁcacy of the 2-input CRISPRks strains via room
temperature kinetic growth assays, 10 μL of the 100X dilution of each sample was
inoculated into 190 uL LB broth supplemented with 100 μg/mL spectinomycin or 34
μg/mL chloramphenicol in a 96-well plate, and read in a plate reader (Biotek
Powerwave HT) at room temperature (22 °C) for 24 h (kinetic read, 5 sec shake
followed by absorbance reading at 600 nm [Abs600] at 20 min intervals). Additionally,
at 3 h and 24 h, kinetic growth assay cultures were sampled, serially diluted, and plated
on LB agar supplemented with 100 μg/mL spectinomycin or 34 μg/mL
chloramphenicol, and incubated overnight at 37 °C prior to colony enumeration.
Kill switch functionality assay. To assess whether colonies that survived kill switch
assays maintained functional kill switches, three no gRNA control colonies and the
speciﬁed number of surviving kill switch colonies were transferred to 600 μL LB in
96-deep well plates (E951032808, Fisher Scientiﬁc). The plates were then incubated
at 37 °C and 250 rpm for 3 h and diluted 20X into 600 μL of fresh LB with and
without 500 ng/mL aTc. After 3 h of induction, the Abs600 was measured for each
culture, and the ratio of uninduced Abs600 to induced Abs600 was determined.
Colonies with non-functional kill switches were deﬁned as having Abs600 ratios
within three standard deviations of the Abs600 ratio of the no gRNA control.

incubated overnight at 37 °C to allow for moderate curing of the ampicillinresistant modiﬁed pMP11 plasmid. Colonies from the plate were streaked onto LB
agar plates with and without ampicillin to identify colonies with successful curing
of the modiﬁed pMP11 plasmid. gRNA kill switch plasmids were constructed
containing another constitutive InfA expression cassette. Cells containing only
pAGR384 were transformed with the InfA-expressing gRNA kill switch plasmids
and incubated overnight at 42 °C to cure pAGR384. Successful curing of pAGR384
was conﬁrmed by streaking colonies on agar plates with spectinomycin only and
with both spectinomycin and kanamycin.
Growth and ﬂuorescence measurements. Population absorbances at 600 nm
(Abs600) were measured in 96-well black assay microplates (07-000-088, Fisher
Scientiﬁc) using a Tecan microplate reader (Inﬁnite M200 Pro) and Tecan
i-Control and converted to optical density OD600 when necessary. To measure
GFP ﬂuorescence, culture samples were transferred to 200 μL ﬁltered 0.9% (w/v)
saline supplemented with 2 mg/ml kanamycin in 96-well clear round bottom assay
microplates (353910, Corning) for measurements. Flow cytometry analysis was
carried out using a Millipore Guava EasyCyte High Throughput Flow Cytometer
and Guavasoft 2.7 software with a 488 nm excitation laser and a 512/18 nm
emission ﬁlter. 10000 events for each sample, gated by forward (minimum/maximum of 20/600) and side scatter (minimum/maximum of 30/2000), were measured at a ﬂow rate 0.59 μl/s. FlowJo (TreeStar Inc.) was used to obtain the average
ﬂuorescence of the population. The ﬂuorescence (au) of each sample was calculated
using the following formula: Fs = Fexperiment – FEcN, where Fs, Fexperiment, and FEcN
respectively represent the reported sample ﬂuorescence, measured sample ﬂuorescence, and autoﬂuorescence (background ﬂuorescence of EcN lacking GFP).
Characterization of TlpA temperature sensors in EcN. The PtlpA promoter and tlpA
gene were PCR ampliﬁed from Salmonella typhimurium SL1344 genomic DNA and
inserted upstream of gfpmut3 to form a negative feedback operon. To convert tlpA
to the modiﬁed tlpA (translated to the protein TlpA*) developed by Pirner et al.,
the following amino acid substitutions were inserted into the tlpA gene: P60L,
G135V, K187R, K202I, and L208Q30. After transforming EcN with each plasmid,
single colonies were transferred to 5 mL of LB and incubated overnight at 37 °C
and 250 rpm. The following day, cultures were diluted 1000X into 50 μL of LB in
PCR tubes30 (T3202N, Fisher Scientiﬁc). The PCR tubes were incubated in a
thermocycler running temperature gradients between 31.5–45.5 °C (TlpA) or
31–37.5 °C (TlpA*) for 24 h. The GFP ﬂuorescence of the cultures was then
quantiﬁed by ﬂow cytometry as described above.
Incorporating and optimizing temperature sensing in the kill switch. The PtlpA-tlpA*
negative feedback cassette was inserted in place of the constitutive promoter
controlling TetR expression on the gRNA kill switch plasmid. To optimize the
expression and stability of TetR in the kill switch, a tetR RBS library and a
C-terminal SsrA degradation tag library were simultaneously inserted into the
plasmid (Supplementary Table 6). The RBS library was designed using the De
Novo RBS Library Calculator v2.1 to have 128 different variants with translation
initiation rates spanning 20−100,000 au70. The initial RBS had a translation
initiation rate of 1,500 au. The SsrA degradation tag library was constructed by
randomly mutagenizing the three nucleotides in the third to last codon of the SsrA
degradation tag71. The total number of potential unique construct variants was
3,328. The library was generated in E. coli DH10B and tested in EcN.
Hill equation ﬁtting. The Hill equation (Eq. 1) was used to ﬁt lines to the ﬂuorescence, CFU, and fraction viable data. The model was ﬁt to the experimentally
collected data by minimizing the root mean square error (RMSE; Eq. 2). Fitted
values are listed in Supplementary Table 1.


Transforming gRNA plasmids into Ptet-cas9 integration strains. A temperaturecurable TetR expression plasmid was constructed with a constitutive TetR expression
cassette, a temperature-sensitive oriR101 origin, and kanamycin resistance gene
(pAGR377). EcN strains with Ptet-cas9 genomic integrations were transformed with
this plasmid, plated on LB agar with kanamycin, and incubated overnight at 30 °C.
Cells with the pAGR377 were then made electrocompetent and transformed with the
gRNA kill switch plasmids. Transformed cells were recovered in 600 μL SOC at 30 °C
for 1 h. The cells were then plated onto LB agar with spectinomycin to select for the
kill switch plasmids and incubated overnight at 42 °C to cure pAGR377. Successful
curing of pAGR377 was conﬁrmed by streaking colonies on agar plates with spectinomycin only and with both spectinomycin and kanamycin.
Generating antibiotic-independent kill switches. To remove the antibiotic dependence of the kill switches, the infA essential gene was knocked out of the genome
and constitutively expressed on the plasmid of interest39,40. To generate an infA
knockout EcN strain, the pMP11 CRISPR plasmid ﬁrst was modiﬁed to constitutively express InfA (pAGR309). The recombination protocol described above
was then used to perform and conﬁrm the knockout. Next, the TetR expression
plasmid was modiﬁed to also constitutively express InfA (pAGR384). The infA
knockout strain containing the modiﬁed pMP11 plasmid was then transformed
with AGR384 and plated on LB agar with kanamycin. The transformants were

F ¼ F min þ

F max  F min
 n
1 þ K½LA


ð1Þ

where
F= Calculated ﬂuorescence, CFUs/mL. or Fraction Viable
Fmax= Maximum ﬂuorescence, CFUs/mL. or Fraction Viable
Fmin = Minimum ﬂuorescence, CFUs/mL. or Fraction Viable
KA = Half maximal constant
n = Hill coefﬁcient
[L] = Ligand concentration or temperature

RMSE ¼

vﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ

2
u
u∑N
t N¼1 F  F exp

ð2Þ

N

where
RMSE = Root mean squared error
F = Calculated ﬂuorescence, CFUs/mL, or Fraction Viable
Fexp = Actual experimental ﬂuorescence, CFUs/mL, or Fraction Viable
N = Number of data points
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Quantiﬁcation and statistical analysis. All statistical tests were performed using
GraphPad Prism or Excel. All statistical details of experiments, including signiﬁcance criteria, sample size, deﬁnition of center, and dispersion measures can be
found in the ﬁgure legends, in the Results section, or in the Source Data ﬁle. Sample
sizes for animal experiments, reporter assays, and viability assays were chosen
based on our previous work13,72 and the literature, and represent sample sizes
routinely used for these methods. No sample size calculations were performed
during the design of experiments. Samples were randomized during group
assignment in all experiments. No samples were excluded from analyses. The
Investigators were not blinded to allocation during experiments and outcome
assessment.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.

Data availability
All source data and plasmid maps have been deposited to Mendeley Data (DOI:
10.17632/dwhfp2ycyw.1). Any additional information is available from the Lead Contact
upon request. Plasmids and strains generated in this paper are available upon request
from the Lead Contact. This study did not generate additional new unique reagents.
Source data is available in the Source Data ﬁle. Source data are provided with this paper.
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